Johnson & Johnson (NYSE: JNJ) — Company Overview, News & Financial Data
Johnson & Johnson is a global healthcare company providing consumer, pharmaceutical, and medical device products.
Johnson & Johnson
Johnson & Johnson is a global healthcare company headquartered in New Brunswick, New Jersey, that researches, develops, manufactures, and markets human health products worldwide. Operating through its Innovative Medicine and MedTech divisions, the company produces prescription pharmaceuticals and medical devices. Its product portfolio spans major therapeutic areas including oncology, immunology, neuroscience, and cardiopulmonary diseases, as well as medical technology solutions for cardiovascular, surgical, orthopaedic, and ophthalmic conditions. The company conducts research and clinical development facilities globally, distributing its products through wholesale distributors, hospitals, retail pharmacies, and healthcare institutions across North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.
Snapshot
Operations
Products and/or services of Johnson & Johnson
- Oncology: Development and commercialization of targeted pharmaceutical therapeutics and cellular therapies, including CAR-T treatments for hematologic malignancies such as multiple myeloma and advanced prostate cancer, serving patients across worldwide healthcare networks.
- Immunology: Research, manufacturing, and global distribution of biological therapies targeting severe autoimmune and chronic inflammatory conditions, including inflammatory bowel disease, psoriasis, psoriatic arthritis, and rare immune-mediated hematologic disorders across international markets.
- Neuroscience: Production and supply of specialized central nervous system pharmaceuticals designed to manage complex neurological and psychiatric conditions, including treatment-resistant major depressive disorder, schizophrenia, and related brain health disorders globally.
- Cardiovascular Technology: Design, production, and distribution of interventional medical devices and electrophysiology tools, including ablation catheters and structural heart systems used in treating cardiac arrhythmias such as atrial fibrillation in clinical settings worldwide.
- Surgical Solutions: Manufacturing and distribution of advanced surgical instrumentation, wound closure tools, and digital surgical technology platforms, integrating artificial intelligence and robotic guidance systems for open and minimally invasive procedures across global surgical centers.
- Orthopaedics: Development, manufacture, and global distribution of orthopaedic joint reconstruction systems, trauma hardware, spinal implants, and specialized surgical instrumentation supplied to healthcare institutions and orthopaedic surgery centers worldwide.
Johnson & Johnson executive team
- Joaquin DuatoCEO & Chairman
- Joseph James WolkExecutive VP & CFO
- John C. ReedExecutive Vice President of Innovative Medicine and R&D
- Timothy SchmidExecutive VP & Worldwide Chairman of MedTech
- Robert J. Decker Jr.Controller & Chief Accounting Officer
- James SwansonExecutive VP & Chief Information Officer
- Ryan KoorsVice President of Investor Relations
- Dirk BrinckmanChief Compliance Officer
- Elizabeth ForminardExecutive VP & Chief Legal Officer
- Kristen Blair MulhollandExecutive VP & Chief Human Resources Officer
Latest news about Johnson & Johnson
Johnson & Johnson reports 35% Crohn's fistula remission
United StatesJohnson & Johnson reports $25.4 billion Q3 sales
United StatesJohnson & Johnson reports robust 2-year ICOTYDE results in plaque psoriasis
United StatesJohnson & Johnson reports sustained psoriasis skin clearance
United StatesJohnson & Johnson reports TREMFYA trial results
United StatesJohnson & Johnson reports CARVYKTI five-year data
United States
Dividend history
Dividends per share paid by Johnson & Johnson, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $5.3200 |
| FY2025 | — | — | — | $5.1400 |
| FY2024 | — | — | — | $4.9100 |
| FY2023 | — | — | — | $4.7000 |
| FY2022 | — | — | — | $4.4500 |
Key financials
Reported results for Johnson & Johnson, in USD.
- Market cap
- 662.5B
- Revenue (TTM)
- 99.3B
- P/E ratio
- 41.8
- EPS (diluted, TTM)
- 6.6
- Dividend yield
- 1.9%
- Profit margin
- 16.2%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 94.2B | 25.6B | 26.8B | |
| 88.8B | 22.1B | 14.1B | |
| 85.2B | 21.9B | 35.2B | |
| 80B | 21B | 17.9B |